Sutro Biopharma, Inc.
STRO
$0.9026
-$0.3974-30.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -59.64% | 230.90% | 197.83% | 106.66% | 126.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -59.64% | 230.90% | 197.83% | 106.66% | 126.84% |
| Cost of Revenue | 5.67% | -61.02% | -68.08% | -80.00% | -91.37% |
| Gross Profit | -65.09% | 178.23% | 220.86% | 273.19% | 304.47% |
| SG&A Expenses | -22.58% | -7.06% | -4.52% | -0.37% | 5.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.66% | 26.36% | 27.71% | 24.73% | 23.53% |
| Operating Income | -167.09% | 28.41% | 33.18% | 21.52% | 30.76% |
| Income Before Tax | -154.06% | 36.41% | 24.85% | 23.65% | 24.08% |
| Income Tax Expenses | -87.01% | 563.10% | 3,133.33% | 514.75% | 627.68% |
| Earnings from Continuing Operations | -112.99% | 28.12% | 12.76% | 11.67% | 10.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -112.99% | 28.12% | 12.76% | 11.67% | 10.41% |
| EBIT | -167.09% | 28.41% | 33.18% | 21.52% | 30.76% |
| EBITDA | -180.41% | 29.75% | 35.02% | 23.32% | 33.10% |
| EPS Basic | -67.78% | 44.21% | 25.39% | 20.76% | 24.39% |
| Normalized Basic EPS | -104.78% | 40.20% | 35.83% | 21.66% | 36.28% |
| EPS Diluted | -67.78% | 44.21% | 25.39% | 20.76% | 24.39% |
| Normalized Diluted EPS | -104.78% | 40.20% | 35.83% | 21.66% | 36.28% |
| Average Basic Shares Outstanding | 27.68% | 20.67% | 15.65% | 13.13% | 18.60% |
| Average Diluted Shares Outstanding | 27.68% | 20.67% | 15.65% | 13.13% | 18.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |